Ranbaxy-Pfizer Settlement Could Set Indian Generics Trend
This article was originally published in PharmAsia News
Executive Summary
The settlement between India's Ranbaxy Laboratories and U.S. drugmaker Pfizer could set a precedent for similar agreements between generics and brand-drug firms. Most of India's leading generics makers are involved in court battles over patents on branded drugs, spending $128.1 million on legal efforts. Because of the Pfizer-Ranbaxy settlement, other Indian generics may be more willing to reach out-of-court settlements. A Novartis India official said, "The trend is definitely going to catch on." (Click here for more